| Type 2 Diabetes Mellitus |
1 |
1 |
| Patient Safety |
0 |
0.9 |
| Adverse Effects |
0 |
0.54 |
| Adherence |
0 |
0.95 |
| Clinical Guidelines |
0 |
0.45 |
| Hypertension |
0 |
0.38 |
| Health Care Cost |
0 |
0.27 |
| Myocardial Infarction (MI) |
0 |
0.25 |
| Diarrhea |
0 |
0.21 |
| Revenue and Practice Management |
0 |
0.21 |
| Canada |
0 |
0.18 |
| DPP-4 Inhibitors |
0 |
0.18 |
| Lipids Management |
0 |
0.18 |
| Salary and Compensation |
0 |
0.18 |
| Cardiovascular Risk Management |
0 |
0.1 |
| Type 1 Diabetes Mellitus |
0 |
0.1 |
| Antihypertensive Agents |
0 |
0.09 |
| Cancer |
0 |
0.09 |
| Cardiovascular disease |
0 |
0.09 |
| Diabetic Ketoacidosis |
0 |
0.09 |
| Dorsum |
0 |
0.09 |
| Exercise |
0 |
0.09 |
| Infarction |
0 |
0.09 |
| Insulin Analog |
0 |
0.09 |
| Nausea |
0 |
0.09 |
| New York |
0 |
0.09 |
| Orbit |
0 |
0.09 |
| Primary Care |
0 |
0.09 |
| Receptors |
0 |
0.09 |
| Statins |
0 |
0.09 |
| Stomach |
0 |
0.09 |
| Sulfonylureas |
0 |
0.09 |